SCHEMBL2902775

SCHEMBL2902775

O=C(C=Cc1cccc(Cl)c1)N1CCC(=O)N(CCN2CCOCC2)CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 5/20 0.51
ICAM1 P05362 5/20 0.51
ITGAL P20701 5/20 0.51
MAPK1 P28482 1/20 0.51
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 1/20 0.50
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902774 1.00 ITGB2 (0.51) ITGB2ICAM1ITGALMAPK1RAB9A
SCHEMBL2904336 0.92 MEN1 (0.51) ITGB2ICAM1ITGALMAPK1MEN1
SCHEMBL2904334 0.92 MEN1 (0.51) ITGB2ICAM1ITGALMAPK1MEN1
SCHEMBL2904467 0.89 ALDH1A1 (0.51) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL2904465 0.89 ALDH1A1 (0.51) ITGB2ICAM1ITGALMEN1KMT2A
SCHEMBL2904594 0.88 NPC1 (0.67) ITGB2ICAM1ITGALRAB9ANPC1
SCHEMBL2904598 0.88 NPC1 (0.67) ITGB2ICAM1ITGALRAB9ANPC1
SCHEMBL2902131 0.86 MEN1 (0.53) ITGB2ICAM1ITGALMAPK1RAB9A
SCHEMBL2902128 0.86 MEN1 (0.53) ITGB2ICAM1ITGALMAPK1RAB9A
SCHEMBL2897188 0.86 MEN1 (0.56) ITGB2ICAM1ITGALMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 ITGB2 1934/4885ICAM1 1281/4885ITGAL 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.